T-LGL LEUKEMIA
Clinical trials for T-LGL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new T-LGL LEUKEMIA trials appear
Sign up with your email to follow new studies for T-LGL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Old drug, new hope: thalidomide shows promise for rare leukemia
Disease control Recruiting nowThis study tests thalidomide alone as a treatment for symptomatic large granular lymphocytic leukemia (LGLL), a rare blood cancer. About 48 adults will take thalidomide daily for up to 3 cycles; if it doesn't work well enough, methotrexate is added. The goal is to see if thalidom…
Matched conditions: T-LGL LEUKEMIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New hope for rare blood cancers: targeted drug shows promise
Disease control Recruiting nowThis study tests a drug called golidocitnib in people with slow-growing but hard-to-treat T/NK-cell lymphomas that have come back or not responded to prior therapy. About 48 adults will receive the drug to see if it can shrink tumors and control the disease. The goal is to improv…
Matched conditions: T-LGL LEUKEMIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 04, 2026 16:19 UTC
-
Massive new registry tracks 8,000 blood cancer patients for decades
Knowledge-focused Recruiting nowThis study is a long-term registry that follows up to 8,000 people with chronic lymphocytic leukemia (CLL) and similar blood cancers. It does not test any new treatment but instead collects information on survival and disease course over many years. Participants must be 18 or old…
Matched conditions: T-LGL LEUKEMIA
Sponsor: German CLL Study Group • Aim: Knowledge-focused
Last updated May 12, 2026 13:39 UTC